Our results demonstrate that IAPs are valid molecular targets for modulating TRAIL sensitivity in prostate cancer cells, and show that blocking IAPs achieves improved efficacy and overcomes resistance to TRAIL. Here, TNFSF10 is linked to prostate carcinoma.